Flecainide induced ventricular tachycardia (torsades de pointes). 2003

Jerome Thevenin, and Antoine Da Costa, and Frederic Roche, and Cecile Romeyer, and Marc Messier, and Karl Isaaz
Division of Cardiology, University Jean Monnet of Saint-Etienne, France.

This case report describes a 68-year-old woman presenting with flecainide induced syncope due to torsades de pointes (TP) ventricular tachycardia. Before TP onset, the QTc interval reached 680 ms without changes in QRS duration. None of the usual triggers were found. Prolongation of QT under flecaïnide is exceptional and the occurrence of TP without concurrent triggers has not been reported in the literature.

UI MeSH Term Description Entries
D004562 Electrocardiography Recording of the moment-to-moment electromotive forces of the HEART as projected onto various sites on the body's surface, delineated as a scalar function of time. The recording is monitored by a tracing on slow moving chart paper or by observing it on a cardioscope, which is a CATHODE RAY TUBE DISPLAY. 12-Lead ECG,12-Lead EKG,12-Lead Electrocardiography,Cardiography,ECG,EKG,Electrocardiogram,Electrocardiograph,12 Lead ECG,12 Lead EKG,12 Lead Electrocardiography,12-Lead ECGs,12-Lead EKGs,12-Lead Electrocardiographies,Cardiographies,ECG, 12-Lead,EKG, 12-Lead,Electrocardiograms,Electrocardiographies, 12-Lead,Electrocardiographs,Electrocardiography, 12-Lead
D005260 Female Females
D005424 Flecainide A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS. Flecainide Acetate,Apocard,Flecadura,Flecainid-Isis,Flecainide Monoacetate,Flecainide Monoacetate, (+-)-Isomer,Flecainide Monoacetate, (R)-Isomer,Flecainide Monoacetate, (S)-Isomer,Flecainide, (R)-Isomer,Flecainide, (S)-Isomer,Flecainide, 5-HO-N-(6-oxo)-Derivative,Flecainide, 5-HO-N-(6-oxo)-Derivative, (+-)-Isomer,Flecatab,Flécaïne,R818,Tambocor,Flecainid Isis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000889 Anti-Arrhythmia Agents Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. Anti-Arrhythmia Agent,Anti-Arrhythmia Drug,Anti-Arrhythmic,Antiarrhythmia Agent,Antiarrhythmia Drug,Antiarrhythmic Drug,Antifibrillatory Agent,Antifibrillatory Agents,Cardiac Depressant,Cardiac Depressants,Myocardial Depressant,Myocardial Depressants,Anti-Arrhythmia Drugs,Anti-Arrhythmics,Antiarrhythmia Agents,Antiarrhythmia Drugs,Antiarrhythmic Drugs,Agent, Anti-Arrhythmia,Agent, Antiarrhythmia,Agent, Antifibrillatory,Agents, Anti-Arrhythmia,Agents, Antiarrhythmia,Agents, Antifibrillatory,Anti Arrhythmia Agent,Anti Arrhythmia Agents,Anti Arrhythmia Drug,Anti Arrhythmia Drugs,Anti Arrhythmic,Anti Arrhythmics,Depressant, Cardiac,Depressant, Myocardial,Depressants, Cardiac,Depressants, Myocardial,Drug, Anti-Arrhythmia,Drug, Antiarrhythmia,Drug, Antiarrhythmic,Drugs, Anti-Arrhythmia,Drugs, Antiarrhythmia,Drugs, Antiarrhythmic
D016171 Torsades de Pointes A malignant form of polymorphic ventricular tachycardia that is characterized by HEART RATE between 200 and 250 beats per minute, and QRS complexes with changing amplitude and twisting of the points. The term also describes the syndrome of tachycardia with prolonged ventricular repolarization, long QT intervals exceeding 500 milliseconds or BRADYCARDIA. Torsades de pointes may be self-limited or may progress to VENTRICULAR FIBRILLATION. Torsade de Pointes,Pointes, Torsade de,Pointes, Torsades de,de Pointes, Torsade,de Pointes, Torsades

Related Publications

Jerome Thevenin, and Antoine Da Costa, and Frederic Roche, and Cecile Romeyer, and Marc Messier, and Karl Isaaz
January 1977, Archivos del Instituto de Cardiologia de Mexico,
Jerome Thevenin, and Antoine Da Costa, and Frederic Roche, and Cecile Romeyer, and Marc Messier, and Karl Isaaz
January 2001, Pacing and clinical electrophysiology : PACE,
Jerome Thevenin, and Antoine Da Costa, and Frederic Roche, and Cecile Romeyer, and Marc Messier, and Karl Isaaz
February 2003, Orvosi hetilap,
Jerome Thevenin, and Antoine Da Costa, and Frederic Roche, and Cecile Romeyer, and Marc Messier, and Karl Isaaz
January 2010, Internal medicine (Tokyo, Japan),
Jerome Thevenin, and Antoine Da Costa, and Frederic Roche, and Cecile Romeyer, and Marc Messier, and Karl Isaaz
May 1996, Ugeskrift for laeger,
Jerome Thevenin, and Antoine Da Costa, and Frederic Roche, and Cecile Romeyer, and Marc Messier, and Karl Isaaz
August 1991, Lancet (London, England),
Jerome Thevenin, and Antoine Da Costa, and Frederic Roche, and Cecile Romeyer, and Marc Messier, and Karl Isaaz
September 1983, The American journal of cardiology,
Jerome Thevenin, and Antoine Da Costa, and Frederic Roche, and Cecile Romeyer, and Marc Messier, and Karl Isaaz
July 1984, The American journal of cardiology,
Jerome Thevenin, and Antoine Da Costa, and Frederic Roche, and Cecile Romeyer, and Marc Messier, and Karl Isaaz
July 2016, Ugeskrift for laeger,
Jerome Thevenin, and Antoine Da Costa, and Frederic Roche, and Cecile Romeyer, and Marc Messier, and Karl Isaaz
June 2001, Journal of cardiovascular electrophysiology,
Copied contents to your clipboard!